Pfizer Inc.
PFE
$25.94
$0.190.74%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/29/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.76B | 17.70B | 13.28B | 14.88B | 14.57B |
| Total Other Revenue | -- | -- | -- | -- | 1.91B |
| Total Revenue | 17.76B | 17.70B | 13.28B | 14.88B | 14.57B |
| Cost of Revenue | 5.74B | 4.87B | 2.77B | 3.04B | 7.27B |
| Gross Profit | 12.02B | 12.83B | 10.52B | 11.84B | 7.30B |
| SG&A Expenses | 4.74B | 3.12B | 3.56B | 3.35B | 4.13B |
| Depreciation & Amortization | 1.36B | 1.31B | 1.31B | 1.31B | 1.27B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.94B | 11.86B | 10.31B | 10.17B | 15.54B |
| Operating Income | 2.83B | 5.84B | 2.98B | 4.71B | -965.00M |
| Income Before Tax | -10.00M | 4.72B | -103.00M | 3.42B | -4.13B |
| Income Tax Expenses | -421.00M | 234.00M | -134.00M | 293.00M | -795.00M |
| Earnings from Continuing Operations | 411.00M | 4.48B | 31.00M | 3.13B | -3.33B |
| Earnings from Discontinued Operations | 7.00M | -8.00M | 17.00M | -5.00M | -26.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.00M | -8.00M | -7.00M | -8.00M | -9.00M |
| Net Income | 410.00M | 4.47B | 41.00M | 3.12B | -3.37B |
| EBIT | 2.83B | 5.84B | 2.98B | 4.71B | -965.00M |
| EBITDA | 4.61B | 7.58B | 4.70B | 6.44B | 701.00M |
| EPS Basic | 0.07 | 0.79 | 0.01 | 0.55 | -0.60 |
| Normalized Basic EPS | 0.35 | 0.56 | 0.28 | 0.45 | -0.09 |
| EPS Diluted | 0.07 | 0.79 | 0.01 | 0.55 | -0.60 |
| Normalized Diluted EPS | 0.34 | 0.56 | 0.27 | 0.44 | -0.09 |
| Average Basic Shares Outstanding | 5.67B | 5.67B | 5.67B | 5.66B | 5.65B |
| Average Diluted Shares Outstanding | 5.70B | 5.71B | 5.70B | 5.70B | 5.65B |
| Dividend Per Share | 0.42 | 0.42 | 0.42 | 0.42 | 0.41 |
| Payout Ratio | 580.49% | 53.30% | 5,804.88% | 76.15% | -68.71% |
